The U.S. Food and Drug Administration (FDA) has approved Cefovecin Sodium for Injection for use in dogs and cats to treat skin infections, including abscesses and wounds caused by specific bacterial strains. As indicated in the Freedom of Information Summary (FOI): "Dogs Cefovecin Sodium for Injection is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G). Cats Cefovecin Sodium for Injection is indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida." The injectable antimicrobial drug contains the same active ingredient as Convenia, first approved in 2008, and includes no inactive ingredients that would alter its bioavailability. The drug, sponsored by Qilu Animal Health Products Co., Ltd. in China, is available by prescription in multi-use vials reconstituted to 80 mg/mL. For more information, visit the FDA website.
